L. Micco

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
L Micco, L. Micco, Lorenzo Micco
Publication record
37 papers · 1,397 citations · H-index 9

PAPERS

Effect of in-vivo hepatitis B viral load suppression after interferon exposure on natural killer and T-cell responsiveness
20170 citationsauthor #4
Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo
201669 citationsauthor #3
NK cell function is restored with sequential NUC therapy and correlates with treatment response in Chronic Hepatitis B
20150 citationsauthor #3
P0485 : Functional immune restoration correlates with HBsAg decline and may predict treatment response on sequential NUC therapy in chronic hepatitis B
20150 citationsauthor #3
PTU-116 Functional immune restoration correlates with HBSAG decline and may predict treatment response on sequential NUC therapy in CHB
20150 citationsauthor #3
P152 SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON-ALPHA EXPOSURE RESTORES INNATE IMMUNE RESPONSES CONFERRING A TREATMENT ADVANTAGE OVER NUC MONOTHERAPY IN CHRONIC HEPATITIS B
20140 citationsauthor #3
Sa1313 Sequential Nuc Therapy Following Pegylated Interferon-Alpha Exposure Restores Innate Immune Responses Conferring a Treatment Advantage Over Nuc Monotherapy in Chronic Hepatitis B
20140 citationsauthor #3
Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B
20141 citationsauthor #4
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.
2013238 citationsauthor #1
Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion
2013333 citationsauthor #7
PMO-177 Maximal boosting of innate immunity during pegylated interferon-α therapy is reached at 48 weeks in e-antigen positive chronic hepatitis B
20120 citationsauthor #4
441 MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-APLHA THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B
20120 citationsauthor #4
Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool.
201265 citationsauthor #2
Mo1837 Maximal Boosting of Innate Immunity During Pegylated Interferon-Aplha Therapy is Reached at 48 Weeks in E-Antigen Positive Chronic Hepatitis B
20120 citationsauthor #4
Susceptibility of T cells to death ligand-mediated deletion in the liver of chronic hepatitis B virus (CHB) infected patients
20110 citationsauthor #3
Pegylated interferon α modulates innate immunity in eAg positive chronic hepatitis B and determines changes in HBsAg quantification
20110 citationsauthor #2
70 PEGYLATED INTERFERON ALPHA MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION
20112 citationsauthor #2
309 ALTERING CO-INHIBITORY AND CO-STIMULATORY PATHWAYS TO RESTORE ANTI-VIRAL T CELL RESPONSES IN CHRONIC HBV INFECTION
20110 citationsauthor #6
301 Pegylated Interferon-Alpha Potently Augments Nk Cell Antiviral Effector Function
20110 citationsauthor #1
Innate and adaptive immune modulation by Pegylated Interferon Alpha therapy in chronic hepatitis B
20110 citationsauthor #1
T-47 High prevalence of occult hepatitis C virus infection in non alcholic steatohepatitis and cryptogenetic liver diseases
20114 citationsauthor #6
Vitamins in the treatment of chronic viral hepatitis
20119 citationsauthor #7
OC-12 Pegylated interferon-alpha potently augments NK cell antiviral effector function in chronic hepatitis B
20110 citationsauthor #1
Role of the coinhibitory receptor cytotoxic T lymphocyte antigen‐4 on apoptosis‐Prone CD8 T cells in persistent hepatitis B virus infection
2011302 citationsauthor #6
91 FRATRICIDE OF HBV-SPECIFIC CD8 T CELLS BY NK CELLS MEDIATED THROUGH THE TRAIL PATHWAY
20110 citationsauthor #2
Serum hepatitis B surface antigen monitoring in long‐term lamivudine‐treated hepatitis B virus patients
201126 citationsauthor #3
19 HBsAg SERUM LEVELS NEGATIVELY AFFECT HBV SPECIFIC IMMUNE RESPONSE
20100 citationsauthor #3
Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection
2010264 citationsauthor #2
T.N.17 DIFFERENTIAL EFFECTS OF PEGYLATED INTERFERON ALPHA THERAPY ON INNATE AND ADAPTIVE IMMUNE RESPONSES IN CHRONIC HEPATITIS B
20100 citationsauthor #1
9 DIFFERENTIAL EFFECTS OF PEGYLATED INTERFERON ALPHA THERAPY ON INNATE AND ADAPTIVE IMMUNE RESPONSES IN CHRONIC HEPATITIS B
20100 citationsauthor #1
Hepatitis C Virus‐related chronic liver disease in elderly patients: an Italian cross‐sectional study
201015 citationsauthor #8
619 NEGATIVE CORRELATION BETWEEN HBSAG SERUM LEVELS AND HBV-SPECIFIC IMMUNE RESPONSES
20100 citationsauthor #3
Alcohol and viral hepatitis: a mini-review.
200966 citationsauthor #2
Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report
20093 citationsauthor #1
Should HBsAg-positive grafts considered marginal for orthotopic liver transplantation?
20090 citationsauthor #1
481 SHOULD HBsAg-POSITIVE GRAFTS CONSIDERED MARGINAL FOR ORTHOTOPIC LIVER TRANSPLANTATION? SINGLE CENTER EXPERIENCE
20090 citationsauthor #2
702 HEPATITIS B SURFACE ANTIGEN SERUM LEVELS AND SPECIFIC T CELLS RESPONSE IMPROVE THE MONITORING OF NUCLEOSIDE ANALOGUES TREATMENT IN HBEAG-NEGATIVE CHRONIC HEPATITIS B
20080 citationsauthor #1

TIMELINE

2008 0 citations

2009 69 citations

2010 279 citations

2011 343 citations

2012 65 citations

2013 571 citations

2014 1 citations

2015 0 citations

2016 69 citations

2017 0 citations

L. Micco

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT